



Selected Papers of William L. White

www.williamwhitepapers.com

Collected papers, interviews, video presentations, photos, and archival documents on the history of addiction treatment and recovery in America.

White, W. (2021). *Psychedelics and addiction recovery: A bibliography of classic and contemporary literature*
Posted at www.williamwhitepapers.com

Psychedelics and Addiction Recovery: A Bibliography of Classic and Contemporary Literature

William L. White

Emeritus Senior Research Consultant
Chestnut Health Systems
bwhite@chestnut.org

- Abramson, H. (1967). *The use of LSD in psychotherapy and alcoholism*. NY: Bobbs-Merrill Co.
- Abuzzahab, F., & Anderson, B. (1971). A review of LSD treatment in alcoholism. *Int Pharmacopsychiatry*, 6, 223-35.
- Albaugh, B. J., & Anderson, P. O. (1974) Peyote in the treatment of alcoholism among American Indians. *Am J Psychiat*, 131(11), 1247-50.
- Alper, K. R. (2001). Ibogaine: a review. *Alkaloids Chem Biol*, 56, 1–38.
- Alper, K. R., Beal, D., Kaplan, C. D. (2001). A contemporary history of ibogaine in the United States and Europe. *Alkaloids Chem Biol*, 56, 249–281.
- Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. *Am J Addict*, 8(3), 234-42.
- Alper, K. R., & Lotsof, H. S. (2007). The use of Ibogaine in the treatment of addictions In: Winkelman M, Roberts T, Eds. *Psychedelic medicine*. Westport, CT: Preager Perspectives; Vol. 2, p. 43-66.
- Alper, K. R., Lotsof, H. S., & Kaplan, C. D. (2008). The ibogaine medical subculture. *J Ethnopharmacol*, 115(1), 9–24.
- Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. *J Forensic Sci*, 57(2), 398-412.
- Argento, E., Capler, R., Thomas, G., Lucas, P. & Tupper, K. W. (2019). Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. *Drug Alcohol Rev*, 38(7), 781-789.
- Argento, E., Tupper, K. W., & Socias, M.E. (2019). The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis. *Int J Drug Policy*, 66, 80-81.
- Barber, M., Gardner, J., Savic, M., & Carter, A. (2020). Ibogaine therapy for addiction: Consumer views from online fora. *Int J Drug Policy*, 83, 102857.

- Berlowitz, I., Walt, H., Ghasarian, C., Mendive, F., & Martin-Soelch, C. (2019). Short-term treatment effects of a substance use disorder therapy involving traditional Amazonian medicine. *Journal of Psychoactive Drugs*, 51 (4), 323–334.
- Blum, K., & Fetterman, S. F. L., & Pascaros, P. (1977). Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale. *Clinical Toxicology*, 11 (4), 459–472.
- Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C. et al., (2018). Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. *Front Pharmacol*, 20, 9:100.
- Bogenschutz, M. P. & Pommy, J. M. (2012). Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. *Drug Test Anal*, 4(7-8), 543-55.
- Bogenschutz M. P., Forcehimes, A. A., Pommy, J.A, Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J.,. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof of-concept study. *J Psychopharmacol*, 29(3), 289–99.
- Bogenschutz, M. P., Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. *Prog In Neuropsychopharmacol Biol Psychiatry*, 64, 250–8.
- Bogenschutz, M. P., & Ross, S. (2018). Therapeutic applications of classic hallucinogens. *Curr Top Behav Neurosci*, 36, 361-391.
- Bouso, J. C. & Riba, J. (2014). Ayahuasca and the treatment of drug addiction. In B. C. Labate and C. Cavnar (eds.), *The Therapeutic Use of Ayahuasca*, DOI: 10.1007/978-3-642-40426-9_6, Springer-Verlag Berlin Heidelberg, pp. 95-109.
- Bowen, W. T., Soskin, R. A., & Chotlos, J. W. (1970). Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism. *Journal of Nervous and Mental Disease*, 150, 111–118.
- Brackenridge, P., (2010). Ibogaine therapy in the treatment of opiate dependency. *Drugs Alcohol Today*, 10 (4), 20–25
- Brown, T. K. (2013). Ibogaine in the treatment of substance dependence. *Curr Drug Abuse Rev*, 6(1), 3-16.
- Brown, T. K., & Alper, K. T. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. *Am J Drug Alcohol Abuse*, 44(1), 24-36.
- Breeksema, J. J., Niemeiher, A. R., Vermetten, E., & Schoevers, R. A. (2020). Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. *CNS Drugs*, 34, 925-946.
- Burdick, B. V., & Adinoff, B. (2013). A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. *Am J Drug Alcohol Abuse*, 39(5), 291-297.
- Calabrese, J. (2007). The therapeutic use of peyote in the Native American church. In: Winkelman M, Roberts T, Eds. *Psychedelic medicine*. Westport, CT: Preager Perspectives; Vol. 2, 29-42.
- Caldwell, W. (1969). *LSD psychotherapy*. NY: Grove Press.
- Chwelos, N., Blewett, D., Smith, C. & Hoffer, A. (1959). Use of LSD-25 in the treatment of chronic alcoholism. *Quarterly Journal of Studies on Alcohol*, 20, 577-590.
- Cloutier-Gill, L.; Wood, E.; Millar, T.; Ferris, C., & Eugenia Socias, M. (2016). Remission of severe opioid use disorder with ibogaine: A case report. *Journal of Psychoactive Drugs*, 48(3), 214-7

- Corkery, J. M. (2018). Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers. *Prog Brain Res*, 242, 217-257.
- Dakwar, E., Anerella, C., Hart, C.L., Levin, F.R., Mathew, S.J., Nunes, E.V., (2014). Therapeutic infusions of ketamine: do the psychoactive effects matter? *Drug Alcohol Depend*, 136, 153e157
- Dakwar, E., Hart, C.L., Levin, F.R., Nunes, E.V., Foltin, R.W. (2016). Cocaine selfadministration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. *Mol. Psychiatry*, 1e6.
- Dakwar, E., Levin, F., Foltin, R.W., Nunes, E.V., Hart, C.L., (2014). The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. *Biol. Psychiatry*, 76, 40e46.
- Dakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., Levin, F. R. (2018). A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. *Neuropharmacology*, 142, 270–6.
- Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., et al.(2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. *Am J Psychiatry*, 176(11), 923–30.
- Das, R.K., Hindocha, C., Freeman, T.P., Lazzarino, A.I., Curran, H.V., Kamboj, S.K. (2015). Assessing the translational feasibility of pharmacological drug memory reconsolidation blockade with memantine in quitting smokers. *Psychopharmacology (Berl)* 232, 3363e3374.
- Davis, A.K., Barsuglia, J.P., Windham-Herman, A.-M., Lynch, M., Polanco, M., (2017). Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. *J. Psychedelic Stud*, 1, 65–73.
- de Veen, B. T. H., Schellekens, A. F. A., Verheij, M. M. M., & Homberg, J. R. (2017). Psilocybin for treating substance use disorders? *Expert Rev Neurother*, 17(2), 203-212.
- DiVito, A. J. & Leger, R.F. (2020). Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. *Mol Biol Rep*, PMID: 32735782
- dos Santos, R.G., (2017). Ibogaine in the Treatment of Alcoholism: A Randomized, DoubleBlind, Placebo-Controlled, Escalating-Dose, Phase 2 Trial. University of Sao Paulo. Details available at: <https://clinicaltrials.gov/ct2/show/study/NCT03380728>.
- Dyck, E. (2006). 'Hitting highs at rock bottom': LSD treatment for alcoholism 1950-1970. *Soc. Hist. Med.*, 19, 313–329.
- Ezquerro-Romano, I., Lawn, W., Krupitsky, E. & Morgan, C. J. A. (2018). Ketamine for the treatment of addiction: Evidence and potential mechanisms. *Neuropharmacology*, 142, 72-82.
- Fernández, X., & Fábregas, J. M. Experience of treatment with ayahuasca for drug addiction in the Brazilian Amazon. In Bia Labate, Clancy Cavnar, Brian Anderson, Bruno Lobao, and Suely Mizumoto. *The Therapeutic Use of Ayahuasca*. 95-109.
- Fabregas, J.M. et al. (2010). Assessment of addiction severity among ritual users of ayahuasca. *Drug Alcohol Depend*, 111, 257–261.

- Frecska, E. (2007). Therapeutic guidelines: Dangers and contra-indications in therapeutic applications of hallucinogens. In: Winkelman M, Roberts T, Eds. *Psychedelic medicine*. Westport, CT: Praeger Perspectives; 1, 69-95.
- Garcia-Romeu, A., Davis, A.K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. *J Psychopharmacol*, 33(9), 1088–101.
- Garcia-Romeu, A. , Davis, A. K. , Erowid, E. , Griffiths, R. R. , & Johnson, M. W. (2020). Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. *Frontiers in Psychiatry*, 10, 955.
- Garcia-Romeu, A., R, Griffiths, R., & W, & Johnson, M. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. *Current Drug Abuse Reviews*, 7 (3), 157–164.
- Garcia-Romeu, A., Richards, W.A., (2018). Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. *Int. Rev. Psychiatr*, 30, 291–316.
- Garrity, J. F. (2000). Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing. *Med Anthropol Q*, 14, 521–542.
- Glick, S.D., Maisonneuve, I.M., (1998). Mechanisms of antiaddictive actions of ibogaine. *Ann. N. Y. Acad. Sci*, 844 (1), 214–226.
- Glick, S.D., Maisonneuve, I.M., (2000). Development of novel medications for drug addiction. The legacy of an African shrub. *Ann. N. Y. Acad. Sci*, 909, 88–103.
- Groff, S. (1970). The use of LSD in psychotherapy. *Journal of Psychedelic Drugs*, 3(1), 52-62;
- Groff, S. (1980). *LSD psychotherapy*. Pomona, California: Hunter House.
- Halpern J. (1996). The use of hallucinogens in the treatment of addiction. *Addict Res*, 4(2), 177-189.
- Halpern, J. H. (2007). Hallucinogens in the treatment of alcoholism and other addictions. In M. J. Winkelman & T. B. Roberts (Eds.), *Psychedelic medicine: New evidence for hallucinogenic substances as treatments* (Vol. 2, pp. 1–14). Westport, CT: Praeger.
- Halpern, J. H. (1996). The use of hallucinogens in the treatment of addiction. *Addict Res*, 4, 177–189.
- Halpern, J. H., & Pope, H. G. (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? *Drug Alcohol Depend*, 69, 109–119.
- Halpern, J. H., Sherwood, A. R., Hudson, J. I., Yurgelun-Todd, D., & Pope, H. G. Jr. (2005). Psychological and cognitive effects of long-term peyote use among Native Americans. *Biol Psychiatry*, 58(8), 624-31.
- Halpern, J. H., Sherwood, A. R., Passie, T., Blackwell, K. C., & Rutenber, K. J. (2008). Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. *Med Sci Monit*, 14(8), SR15-22.
- Hamill, J., Hallak, J., Dursun, S. M., & Baker, G. (2019). Ayahuasca: Psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness. *Curr Neuropharmacol* 17(2), 108-128.
- Hendricks, P. S. (2014). Back to the future: A return to psychedelic treatment models for addiction. *Journal of Psychopharmacology*, 28 (11), 981–982.
- Hendricks, P. S. (2018a). Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. *International Review of Psychiatry*, 30 (4), 331–342.

- Hendricks, P. S. (2018b). Psilocybin treatment of cocaine use disorder. In R.R. Griffiths & M.W. Johnson (Chairs), *Drug addiction treatment with classic psychedelics*. Symposium presented at the 80th annual meeting of the College on Problems of Drug Dependence. San Diego, California
- Hendricks, P., Clark, C. B., Johnson, M., Fontaine, K., & Cropsey, K. (2014). Hallucinogen use predicts reduced recidivism among substance involved offenders under community corrections supervision. *J Psychopharmacol*, 28(1), 62-6.
- Hoffer, A. (1967). A program for the treatment of alcoholism: LSD, malaria and nicotinic acid. In: Abramson, H., Ed., *The use of LSD in psychotherapy and alcoholism*. NY: Bobbs-Merrill Company, Inc.
- Hollister, L. E., Shelton, J., & Krieger, G. (1969). A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. *American Journal of Psychiatry*, 125 (10), 1352–1357.
- Jalal, S., Daher, E., Hilu, R., (2013). A case of death due to ibogaine use for heroin addiction: case report. *Am. J. Addict.*, 22 (3), 302.
- Jerome, L., Schuster, S., & Yazar-Klosinski, B. (2013). Can MDMA play a role in the treatment of substance abuse? *Curr Drug Abuse Rev*, 6, 54-62.
- Johnson, M. W. (In Press) Psychedelics in the treatment of addiction. In: Grob CS, editor. *Handbook of Medical Hallucinogens*. Guilford Press: New York, NY.
- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. (2014). Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *J. Psychopharmacol.*, 28, 983–992.
- Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. *Am J Drug Alcohol Abuse*, 43(1), 55–60.
- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology*, 28 (11), 983–992.
- Johnson, M. W., Garcia-Romeu, A., Johnson, P. S., & Griffiths, R. R. (2017). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. *Journal of Psychopharmacology*, 31 (7), 841–850.
- Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. *Neuropharmacology*, 142, 143–166.
- Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. *Pharmacology & Therapeutics*, 197, 83–102.
- Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. *Journal of Psychopharmacology*, 22 (6), 603–620.
- Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T, & Back, S. E. (2018). Efficacy of ketamine in the treatment of substance use disorders: A systematic review. *Front. Psychiatry*, July, <https://doi.org/10.3389/fpsyt.2018.00277>
- Koenig, X. & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. *Molecules*, 20(2), 2208-28.
- Kolp, E., Friedman, H.L., Young, M.S., Krupitsky, E. (2006). Ketamine enhanced psychotherapy: preliminary clinical observations on its effectiveness in treating alcoholism. *Humanist. Psychol.*, 34, 399

- Krebs, T. S., & Johansen, P. O. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. *Psychopharmacology (Berl)*, 26(7), 994–1002.
- Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, & Grinenko A. (2002). Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. *J Subst Abuse Treat* 2002; 23(4): 273-283.
- Krupitsky, E.M., Burakov, A.M., Dunaevsky, I.V., Romanova, T.N., Slavina, T.Y., Grinenko, A.Y., (2007). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. *J. Psychoact. Drugs*, 39, 13e19.
- Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. *J Psychoactive Drugs*, 29(2), 165–83.
- Labate, B. C., Santos, R. G., Anderson, B. T., Mercante, M., & Barbosa, P. C. R. (2010). The treatment and handling of substance dependency with ayahuasca: Reflections on current and future research. In B. C. Labate & E. MacRae (Eds.), *Ayahuasca, ritual, and religion in Brazil* (pp. 205–227). London, England: Equinox.
- Lattin, D. (2012). *Bill Wilson, LSD and role that psychedelics played in the history of Alcoholics Anonymous*. University of California Press.
- Lea, T., Amada, N., Jungaberle, H., Schecke, H., Scherbaum, N., & Klein, M. (2020). Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. *Psychopharmacology (Berl)*, 237(5), 1521-1532.
- Liester, M. B. (2014). A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects. *Curr Drug Abuse Rev*, 7(3), 146-56.
- Liester, M. B., & Prickett, J. (2012). Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions. *Journal of Psychoactive Drugs*, 44(3), 200–208.
- Loizaga-Velder, A. (2013). A psychotherapeutic view on therapeutic effects of ritual ayahuasca use in the treatment of addiction. *MAPS Bulletin*, 23(1), 36–40.
- Loizaga-Velder, A., & Pazzi, A. L. (2014). Therapist and patient perspectives on ayahuasca-assisted treatment for substance dependence. In In Bia Labate, Clancy Cavnar, Brian Anderson, Bruno Lobao, & Suely Mizumoto. *The Therapeutic Use of Ayahuasca*, pp. 133-152.
- Loizaga-Velder, A. & Verres, R. (2014). Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence--qualitative results. *J Psychoactive Drugs*, 46(1), 63-72.
- Lotsof, H.S., (1995). Ibogaine in the treatment of chemical dependence disorders: clinical perspectives. *MAPS Bull.*, 5 (3), 19–26.
- Lotsof, H. S., & Alexander, N. E. (2001). Case studies of ibogaine treatment: implications for patient management strategies. *Alkaloids Chem Biol*, 56, 293–313.
- Ludwig, A., Levine, J., Stark, L., & Lazar, R. (1969). A clinical study of LSD treatment in alcoholism. *American Journal of Psychiatry*, 126 (1), 59–69.
- Lu, L, Liu, Y., Zhu, W., Shi, J., Liu, Y., Ling, W., & Kosten, T. R. (2009). Traditional medicine in the treatment of drug addiction. *The American Journal of Drug and Alcohol Abuse*, 35 (1), 1–11
- Mabit, J. (2002). Blending traditions: Using indigenous medicinal knowledge to treat drug addiction. *MAPS Bulletin*, 7(2), 25–32.

- Mabit J. (2007). Ayahuasca in the treatment of addictions. In T. B. Robert & M. J. Winkelman (Eds.), *Psychedelic medicine* (vol. 2): *New evidence for hallucinogenic substances as treatments* (pp. 87-103). New York, NY: Praeger.
- Mabit J, Giove R, Vega J. Takiwasi: (1996). The use of Amazonia shamanism to rehabilitate drug addicts. In: Winkelman M, Andritzky W, Eds. *Sacred plants, consciousness and healing: Cross-cultural and interdisciplinary perspectives. Yearbook of cross-cultural medicine and psychotherapy*. Berlin: Verlag und Vertrieb; 257-86.
- Maciulaitis R., Kontrimaviciute V., Bressolle F., & Briedis V. (2008). Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. *Hum Exp Toxicol* 27, 181.
- Mangini M. (1998). Treatment of alcoholism using psychedelic drugs: A review of the program of research. *J Psychoactive Drugs*, 30(4), 381-418.
- Mangini M. (1998). Treatment of alcoholism using psychedelic drugs: A review of the program of research. *J Psychoactive Drugs*, 30(4), 381-418.
- Marta, C. J., Ryan, W. C., Kopelowicz, A. & Koek, R. J. (2015). Mania following use of ibogaine: A case series. *Am J Addict*, 24(3):203-205.
- Mash, D.C., Kovera, C.A., Buck, B.E., Norenberg, M.D., Shapshak, P., Hearn, W.L., SanchezRamos, J., (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. *Ann. N. Y. Acad. Sci.*, 844, 274–292.
- Mash D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D..(2001). Ibogaine in the treatment of heroin withdrawal. *Alkaloids: Chem Biol*, 56, 155-71.
- Mash, D. C., Kovera, C. A., Buch, B. E., et al. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. *Ann NY Acad Sci*, 844, 274-292.
- Mazoyer, C., Carlier, J., Boucher, A., Peoc'h, M., Lemeur, C., Gaillard, Y., (2013). Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. *J. Forensic Sci.*, 58 (6), 1666–1672.
- McAndrew, A., Lawn, W., Stevens, T., Porffy, L., Brandner, B., Morgan, C.J.A. (2017). A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. *Trials*, 18 (159).
- Meisner, J.A., Wilcox, S.R., Richards, J.B., (2016). Ibogaine-associated cardiac arrest and death: case report and review of the literature. *Ther. Adv. Psychopharmacol.*, 6 (2), 95–98.
- Morgan, C., McAndrew, A., Stevens, T., Nutt, D., Lawn, W., (2017). Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. *Curr. Opin. Behav. Sci.*, 13, 71–76.
- Nichols, D. E. (2018). Dark classics in chemical neuroscience: Lysergic Acid Diethylamide (LSD) *ACS Chem Neurosci*, 9(10), 2331-2343.
- Nichols, D.E. (2016). Psychedelics. *Pharmacol. Rev.* 68, 264–355.
- Nichols, D. E., Johnson, M. W. & Nichols, C. D. (2017). Psychedelics as medicines: An emerging new paradigm. *Clin Pharmacol Ther*, 101(2):209-219.
- Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018). The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. *Front Pharmacol*, 9(132), 1–13.

- Noller, G. E; Frampton, C. M.; Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *Am J Drug Alcohol Abuse*, 44(1), 37-46.
- Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. *J Psychopharmacol.*, 32(7), 756–69.
- Paling, F.P., Andrews, L.M., Valk, G.D., Blom, H.J., (2012). Life-threatening complications of ibogaine: three case reports. *Neth. J. Med.*, 70 (9), 422–424.
- Papadodima, S.A., Dona, A., Evaggelakos, C.I., Goutas, N., Athanaselis, S.A., 2013. Ibogaine related sudden death: a case report. *J. Forensic Leg. Med.*, 20 (7), 809–811.
- Perkins, D., Sarris, J., Rossell, S., Bonomo, Y. Forbes, D. Et al (2021) Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. *Aust N Z J Psychiatry*, 4867421998785. Online ahead of print.
- Pisano, V. D. , Putnam, N. P. , Kramer, H. M. , Franciotti, K. J. , Halpern, J. H. , & Holden, S. C. (2017). The association of psychedelic use and opioid use disorders among illicit users in the United States. *Journal of Psychopharmacology*, 31 (5), 606–613.
- Popik, P., Glick, S.D., (1996). Ibogaine, a putatively anti-addictive alkaloid. *Drugs Future*, 21 (11), 1109–1115.
- Prickett, J., & Liester, M. (2014). Hypotheses regarding ayahuasca's potential mechanisms of action in the treatment of addiction. In: Labate B, Cavnar C, Eds. *The therapeutic use of ayahuasca*. Berlin: Springer-Verlag; 2014. pp. 111-132.
- Rhead, J. C., Soskin, R. A., Turek, I., Richards, W. A., Yensen ,R., Kurland, A. A., & Ota, Y. O. (1977), Psychedelic drug (DPT)-assisted psychotherapy with alcoholics: a controlled study. *J Psychedelic Drugs*, 9, 287–300.
- Romeo, B., Hermand, M., Pétilion, A., Karila, L. & Benyamina, A. (2021). Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. *J Psychiatr Res*, 137, 273-282.
- Ross, S. (2012). Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. *Psychiatr Clinics*, 35(2), 357–74.
- Roy, C. (1973) Indian peyotists and alcohol. *Am J Psychiatry*, 130, 329–330.
- Rydzynski, Z., & Gruszczyński, W. (1978). Treatment of alcoholism with psychotomimetic drugs. A follow-up study. *Act Nerv Super (Praha)* 20:81–82
- Rydzynski, Z., Cwynna, R. S., Grzelak, L., Jagiello, W. (1968). Preliminary report on the experience with psychosomimetic drugs in the treatment of alcoholism. *Act Nerv Super (Praha)*, 10, 273. Saunders, C. (1988) Spiritual pain. *J Palliat Care* 4:29–32
- Savage, C. & McCabe, O. (1971). Psychedelic (LSD) therapy of drug addiction. In: *The drug abuse controversy*. Brown, C. and Savage, C. Eds. Baltimore, MD: National Educational Consultants, Inc., pp. 145-163.
- Savage, C., & McCabe, O. L. (1973). Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. *Arch Gen Psychiatry*, 28(6), 808–14.
- Schenberg, E.E., de Castro Comis, M.A., Chaves, B.R., da Silveira, D.X., (2014). Treating drug dependence with the aid of ibogaine: a retrospective study. *J. Psychopharmacol.*, 28 (11), 993–1000.
- Schenberg, E. E., de Castro Comis, M. A., Alexandre, J. F. M., Rasmussen Chaves, B. D., Tófoli, L. F., & da Silveira, D. X. (2017). Treating drug dependence with the aid of ibogaine: a qualitative study. *J Psychedelic Stud.*, 1(1), 10–9.

- Schenberg, E. E., de Castro Comis, M. A., Alexandre, J. F. M., Tófoli, L. F., Rasmussen Chaves, B. D., & da Silveira, D. X. (2017). A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. *J Psychedelic Stud.*, 1(2), 1–10.
- Schep, L. J., Slaughter, R. J., Galea, S., & Newcombe, D. (2016). Ibogaine for treating drug dependence. What is a safe dose? *Drug Alcohol Depend*, 66, 1-5.
- Sessa, B. (2018). Why MDMA therapy for alcohol use disorder? And why now? *Neuropharmacology*, 142, 83-88.
- Sisko, B. (1993). Interrupting drug dependency with ibogaine: a summary of four case histories. *Multidisciplinary Assoc Psychedelic Stud (MAPS) Newslett*, 4, 15–24.
- Smart, R. G., Storm, T., Baker, E. F., & Solursh, L. (1966). A controlled study of lysergide in the treatment of alcoholism. I. The effects on drinking behavior. *Quarterly Journal of Studies on Alcohol*, 27 (3), 469–482.
- Smith, C. M. (1958). A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. *Q J Stud Alcohol*, 19, 406–417.
- Smith, C. M. (1959). Some reflections on the possible therapeutic effects of the hallucinogens; with special reference to alcoholism. *Q J Stud Alcohol*, 20, 292–301.
- Talin, P., & Sanabria, E. (2017). Ayahuasca's entwined efficacy: an ethnographic study of ritual healing from 'addiction'. *Int J Drug Policy*, 44, 23–30.
- Thomas, G., Lucas, P., Capler, R., Tupper, K., & Martin, G. (2013). Ayahuasca-assisted therapy for addictions: Results from a preliminary observational study in Canada. *Current Drug Abuse Reviews*, 6(1), 30–42.
- Tomsovic, M., & Edwards, R. V. (1970). Lysergide treatment of schizophrenic and non-schizophrenic alcoholics; A controlled evaluation. *Quarterly Journal of Studies on Alcohol*, 31 (4), 932–949.
- Tupper, K. W., Wood, E., [...], & Johnson, M. W. (2015). Psychedelic medicine: a re-emerging therapeutic paradigm CMAJ: *Canadian Medical Association Journal*, 187 (14), 1054-1059.
- van Amsterdam, J., Opperhuizen, A., van den Brink, W.. (2011). Harm potential of magic mushroom use: A review. *Regul Toxicol Pharmacol*, 59, 423-9.
- Vastag, B. (2005). Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'. *Science*, 308, 345–346.
- Vlaanderen, L., Martial, L.C., Franssen, E.J., van der Voort, P.H., Oosterwerff, E., Somsen, G.A., (2014). Cardiac arrest after ibogaine ingestion. *Clin. Toxicol. (Phila.)* 52 (6), 642–643.
- Wasko, M. J., Witt-Enderby, P. A., & Surratt, C. K. (2018). DARK Classics in Chemical Neuroscience: Ibogaine. *ACS Chem Neurosci*, 9(10), 2475-2483.
- Wilkins, C., dos Santos, R.G., Sola, J., Aixalá, M., Cura, P., Moreno, E., Alcazar-Coírcles, M.A., Hallak, J.E.C., & Bouso, J., (2017). Detoxification from methadone using low, repeated, and increasing doses of ibogaine: a case report. *J. Psychedelic Stud.*, 1 (1), 29–34.
- Winkelman, M. (2014). Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. *Curr Drug Abuse Rev*, 7(2), 101-16.
- Winkelman, M., (2009). Shamanistic harm reduction practices. Sacred medicines for harm reduction and substance abuse rehabilitation. In: Browne-Miller A, Ed. The Praeger

International Collection on Addictions. Westport, CT: Praeger Perspectives; Vol 3, pp. 247-265, 377-401.

Winkelman, M., & Roberts, T. (2007). Conclusions: Guidelines for implementing the use of psychedelic medicines. In: Winkelman M, Roberts T, Eds. *Psychedelic medicine*. Westport, CT: Praeger Perspectives; Vol. 1, pp. 271-98.

Yaden, D. B., Berghella, A. P., Regier, P. S., Garcia-Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021). Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. *International Journal of Drug Policy*, 98, 103380.

Yaden, D. B., Yaden, M. E., & Griffiths, R. R. (2020). Psychedelics in Psychiatry —Keeping the renaissance from going off the rails. *JAMA Psychiatry*, 78(5), 469-470.